Contrast echocardiography

Indication for Perflutren

Population group: Suitable for both men and women, only adults (18 years old or older)

Perflutren is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular endocardial border delineation with resulting improvement in wall motion visualisation. Perflutren should only be used in patients where the study without contrast enhancement is inconclusive.

For this indication, competent medicine agencies globally authorize below treatments:

0.5-8.7 ml

Route of admnistration


Defined daily dose

0.5 - 8.7 mL

Dosage regimen

From 0.5 To 8.7 mL once every day

Detailed description

The recommended dose is 0.5-3.0 ml per patient. A dose of 3.0 ml is usually sufficient, but some patients may need higher doses. The total dose should not exceed 8.7 ml per patient. The duration of the useful imaging time is 2.5-4.5 minutes for a dose of 0.5-3.0 ml. Perflutren could be repeatedly administered, however, the clinical experience is limited.

Active ingredient

When used in conjunction with diagnostic ultrasound, perflutren provides opacification of cardiac chambers, improvement in delineation of endocardial borders, enhancement of the Doppler signal, and visualisation of wall motion and blood flow within the heart.

Read more about Perflutren

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner